SUBSCRIBE
SUBSCRIBE
News   Policy

GlaxoSmithKline (JOBS) Temporarily Withdraws Avodart Cancer Filing

November 23, 2009 | 
1 min read

Bookmark and Share

Reuters -- GlaxoSmithKline temporarily withdrew its application to U.S. regulators for a new use of its Avodart drug in preventing prostate cancer because of a technical problem with the file, it said on Monday.

Regulatory
GlaxoSmithKline
MORE ON THIS TOPIC
Psychedelic Brain
People
Lykos Loses Five Board Directors After FDA Rejection
January 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Entrance to the U.S. Department of Health and Human Services in Washington, DC
Accelerated approval
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
January 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Could New Leqembi Formulations Boost Lagging Sales in Alzheimer’s?
January 14, 2025
 · 
1 min read
 · 
Kate Goodwin
Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.
Drug pricing
Part D Drugs Almost Doubled in Cost Since Launch, Underscoring Importance of IRA: AARP
January 10, 2025
 · 
3 min read
 · 
Tristan Manalac